Authors
Latest:
Dr. Basu-Mallick on Established and Emerging Biomarker-Directed Therapies in CRCAtrayee Basu-Mallick, MD, highlights established and emerging biomarker-directed therapies in colorectal cancer.
Latest:
PI3K Inhibitors for PIK3CA-Mutated HR+ MBCConsiderations for treating patients with HR+/HER2- metastatic breast cancer with alpelisib, a PI3K inhibitor, following frontline treatment with a CDK4/6 inhibitor.
Latest:
Our Path Forward in Leading a Revolution in Cancer CareChatrick Paul of AstraZeneca shares his perspective on the mission to eradicate cancer as a leading cause of death
Latest:
Review of AENEAS Trial and Similar AgentsExperts in cancer care review the phase 3 AENEAS trial with aumolertinib and the cost-effectiveness.
Latest:
Optimizing Care of Patients With Advanced Prostate Cancer: ConclusionSummarizes the main points and benefits of multidisciplinary prostate cancer care.
Latest:
Cancer Experts at Jersey Shore University Medical Center Implanting First Targeted Liver Tumor Treatment Pumps in PatientsJersey Shore University Medical Center is among the first hospitals in New Jersey to provide the HAI pump, which is offered at few hospitals in the country, enabling the N.J. community to stay close to home for care.
Latest:
Dr Rosen on the Activity of Zotatifin Plus Abemaciclib/Fulvestrant in ER+ Breast CancerEzra Rosen, MD, PhD, discusses the investigation of the triplet combination of zotatifin, abemaciclib, and fulvestrant in a phase 1/2 trial in heavily pretreated patients with estrogen receptor-positive metastatic breast cancer.
Latest:
Optimizing the Selection of Novel Therapy for Patients With Advanced NSCLCClosing out their panel on immunotherapy in non–small cell lung cancer, expert oncologists share key takeaways on the selection of novel therapy in this setting.
Latest:
Dr. Jones on Future Research Efforts in Pancreatic CancerAmy Jones, MD, discusses future research efforts in pancreatic cancer.
Latest:
Dr Marconi on the Investigation of Tamibarotene Plus Azacitidine in Higher-risk MDSGiovanni Marconi, MD, discusses ongoing research with the combination of tamibarotene and azacitidine in patients with higher-risk myelodysplastic syndrome.
Latest:
Dr. Klempner on the Investigation of Adagrasib in KRAS G12C–Mutated mCRCSam Klempner, MD, discusses the investigation of adagrasib in KRAS G12C–mutated metastatic colorectal cancer.
Latest:
Dr Henick on the Use of Neoadjuvant Atezolizumab Plus Chemotherapy in NSCLCBrian Henick, MD, discusses the 3-year updated data from a phase 2 trial investigating treatment with neoadjuvant atezolizumab plus chemotherapy in patients with resectable non–small cell lung cancer.
Latest:
Moving From Passive to Active Clinical Trials EnrollmentThe Herbert Irving Comprehensive Cancer Center has developed processes to actively screen any patient with a relevant mutation for an open trial.
Latest:
Dr Ahmed on a Study of Real-World Outcomes With Brexu-Cel in Relapsed/Refractory MCLNausheen Ahmed, MD, discusses the rationale and design of a subgroup analysis of real-world outcomes with brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma.
Latest:
Dr Eric Singhi Navigates Advocacy, Mentorship, and More in NSCLC ManagementEric K. Singhe, MD, of The University of Texas MD Anderson Cancer Center, discusses the journey of non–smell cell lung cancer treatment through mentorship, advocacy, and more.
Latest:
Dr Kirtane on the Design of the EVEREST-1 Trial Evaluating A2B530 in Solid TumorsKedar Kirtane, MD, discusses the design of the phase 1/2 EVEREST-1 trial, which is evaluating the autologous CAR T-cell therapy A2B530 in patients with advanced solid tumors.
Latest:
Dr Midha on Real-World Data With Teclistamab in Relapsed/Refractory Multiple MyelomaShonali Midha, MD, discusses real-world data with teclistamab in patients with relapsed/refractory multiple myeloma.
Latest:
Dr. Anwer on the Efficacy of CAR T-Cell Therapy in Multiple MyelomaFaiz Anwer, MD, discusses the efficacy of CAR T-cell therapy in multiple myeloma.
Latest:
Dr Malalur on Addressing Unmet Needs in Pancreatic CancerPannaga G. Malalur, MBBS, discusses several unmet needs within pancreatic cancer, including the implementation of updated germline genetic testing guidelines, increased screening of high-risk patients, and improved sequencing of available therapeutics.
Latest:
CAR T Pioneers Describe Challenges Faced in CancerAdvances of chimeric antigen receptor T-cell therapy technologies are in rapid development and under investigation in a range of preclinical and clinical research around the globe.
Latest:
Dr. Kumar on Immunotherapy Combinations in RCCRohit Kumar, MD, discusses the benefits of combining immunotherapy agents with each other or with TKIs in patients with renal cell carcinoma and the unmet needs that remain for patients with RCC who do not respond to immunotherapy.
Latest:
UAMS Winthrop P. Rockefeller Cancer Institute Pushes Liquid Biopsy Research ForwardThe use of a routine blood test to assess and monitor patients with cancer, especially in a longitudinal manner, has long been the holy grail of cancer research.
Latest:
Dr. Patel on Selecting Patients for Treatment With Atezolizumab/Bevacizumab in HCCMonica A. Patel, MD, discusses factors that determine whether a patient with hepatocellular carcinoma is a good candidate to receive a combination of atezolizumab and bevacizumab.
Latest:
Unprecedented Advances Fuel Progress in the Treatment of AL AmyloidosisLight-chain amyloidosis is a rare plasma cell disorder that involves the production of a misfolded amyloidogenic light chain by a plasma cell clone that deposits in various organs leading to organ failure.
Latest:
Dr. Cooper on Leveraging Novel Agents and Combos in Multiple MyelomaDennis Cooper, MD, sheds light on the novel therapeutic regimens available to patients with multiple myeloma.
Latest:
The Future of HCC TreatmentThe panel closes their discussion by highlighting exciting developments on the horizon for the treatment of HCC.
Latest:
Dr Jagannath on the Potential Role for Linvoseltamab in R/R Multiple MyelomaSundar Jagannath, discusses the potential role for linvoseltamab in relapsed/refractory multiple myeloma.
Latest:
Dr. Tewari on the Factors to Consider for Robotic Radical Prostatectomy in Prostate CancerAshutosh K. Tewari, MD, discusses the factors to consider when deciding on a robotic radical prostatectomy for a patient with prostate cancer.
